INTRODUCTION

Melasma, characterized by dark patches on the skin, predominantly affects individuals with Fitzpatrick skin types III-V and is more common among women. Hydroquinone 4% is traditionally the gold standard for melasma treatment due to its efficacy in reducing pigmentation, but alternatives like β-White™, Tyrostat™, and Melanostatine-5™ or a combination of all are being explored for their potentially better safety profiles.

This study aims to determine the efficacy and safety of β-White + Tyrostat, + Melanostatine-5™ creams versus hydroquinone 4% in the treatment of melasma.

A randomized, double-blind clinical trial compared β-White, Tyrostat, and Melanostatine-5 cream to hydroquinone 4% cream in 40 melasma patients. The intervention consisted of 12-week split-face (left-right) application of the said topical medications. Efficacy was measured using modified Melasma Area and Severity Index (mMASI) Score and the Physician’s and Patient’s Global Assessments (PGA). Safety was used by assessing side effects noted during the application. ANOVA and Post hoc tests were used to measure differences in scores.

Forty out of 42 patients were included in the analysis. The trial found that both treatment regimens were effective, with no significant difference in the reduction of melasma severity over 12 weeks. Initially, the experimental group showed more rapid improvement, but by the third month, both groups reported similar outcomes. The experimental group reported no side effects, making it a potentially safer option for long-term management of melasma.

Overall, while hydroquinone remains effective, β-White + Tyrostat + Melanostatine-5 cream offers a viable alternative with potentially fewer side effects, making it an attractive option for patients seeking long-term melasma management.

Refractory dermal melasma is resistant to conventional treatment. Platelet rich plasma (PRP) may help to reduce the pigmentation of melasma. We present a case report on the clinical outcome of 2 patients with melasma, given PRP, as an adjunct therapy. PRP was administered at a monthly interval for 2 sessions in combination with a monthly Q-switched Nd Yag laser treatment and topical alpha arbutin application. A modified melasma area and severity index (MASI) was evaluated by two dermatologists who were blinded. At the follow up on the 3rd months, the MASI score was reduced by mean 33.5% for case 1 and 20% for case 2. There were no clinical complications for case 1. However recurrence of melasma was noted in case 2 by a worsening of the MASI score mean to 53% at the sixth months follow up. In conclusion, intradermal PRP injection as an adjunct to the conventional treatment of melasma presented with differing results in two cases.
Melasma

No abstract available.
Acanthosis Nigricans

Unilateral acanthosis nigricans (AN) is an exceedingly rare disorder, probably viewed as a nevoid disorder and sometimes called nevoid AN, which is characterized by hyperkeratosis, papillomatosis and moderate acanthosis. The lesions of unilateral AN are distributed unilaterally and morphologic features are similar to other forms of AN. It is not associated with a syndrome, endocrinopathy, drugs or cancers. Here we describe a case of unilateral AN in a 16 year-old Korean man who presented with a broad ashy brown hyperpigmented, confluent hyperkeratotic plaque on the right posterior thigh.
Acanthosis Nigricans ; Papilloma ; Thigh

No abstract available.
Acanthosis Nigricans* ; Growth Hormone*

No abstract available.
Acanthosis Nigricans* ; Tretinoin* ; Umbilicus*

No abstract available.
Acanthosis Nigricans* ; Vitiligo*

No abstract available.
Acanthosis Nigricans ; Ear

No abstract available.
Acanthosis Nigricans* ; Hypopigmentation*

No abstract available.
Acanthosis Nigricans ; Diabetes Mellitus